BioTOPics 47 | May 2014
BioTOP-Report 2014
Editorial
The German Capital Region – Biotechnology and Life Sciences are Ready for the Future
3
Biotechnology
The Capital Region – New Jobs and New Companies
4
Pharma
Attractive Location
14
Glycoscience
Glyco Research for Innovations in Health Industry
18
Bioelectronics
The Joint Lab Bioelectronics – A New Platform for the Integration of Microelectronics into Life Sciences 20
Business Location
Excellent Services for Berlin-Brandenburg
24
Spotlight on European Business and Internationalization
The Enterprise Europe
Network Berlin-Brandenburg
26
Biotech Parks
The BioCampus Network Berlin-Brandenburg
34
Addresses 39
Publisher: Berlin Partner für Wirtschaft und Technologie GmbH · BioTOP Berlin-Brandenburg
Fasanenstraße 85 · 10623 Berlin · Germany · Phone +49 30 318622–0 · Fax +49 30 318622–22 · biotop@biotop.de · www.healthcapital.de
Editor: Volker Erb
Design & Production: webersupiran.berlin
Translation: Kate Abbott · Berlin
Photos/Figures: BioTOP or authors and:
Page 14 Paulus Rusyanto/dreamstime.com, Sean Pavone/dreamstime.com Page 21 Warenemy/dreamstime.com, Collpicto/dreamstime.com
Page 27 adimas/Fotolia (Profile Alacris), Noah Clayton/co.don (Profile co.don) Page 30 Werner Popp (Profile organobalance).
Content
3
BioTOPics 47 | May 2014
BioTOP-Report 2014
Editorial
The German Capital Region – Biotechnology and
Life Sciences are Ready for the Future
Berlin-Brandenburg is an extremely attractive location for research and its translation into industrial applications.
The establishment of the Berlin Institute of Health, successful spin-offs and inward investment show that the Ger-
man capital region provides top conditions for the healthcare industry. Berlin is the start-up capital of Germany!
With its new “Healthcare Industries” master plan, the capital re-
gion is setting the course for the sector’s development until 2018.
Basic research, innovation, spin-offs and application – in the fu-
ture, these will remain the four pillars that determine the success-
ful implementation of the cluster strategy in Berlin-Brandenburg.
Biotechnology/pharmaceuticals, medical technology and the
healthcare industries are the focal areas. In the coming years,
biotechnology/pharmaceuticals development will feature:
The creation of new translation platforms in basic research,
clinical research and industrial biotechnology
Max Planck and Fraunhofer Research, as well as the Helmholtz
and Leibnitz Institutes, are drivers of technology transfer and pio-
neers of innovative technologies and products.
Concentration on therapy development through new system
medicine strategies
The Max Delbrück Center for Molecular Medicine and Charité –
Universitätsmedizin Berlin are the umbrella for the new flagship of
German biomedicine.
In diagnostics, focus on the development of companion diag-
nostics
Laboratory medicine, applied research, SMEs and the pharma-
ceuticals industry are pooling their activities for therapy optimiza-
tion in personalized medicine.
In regenerative medicine, concentration on the development of
new cell therapies
The Berlin-Brandenburg Center for Regenerative Therapies
(BCRT), biotechnology SMEs and pharmaceuticals partners in
the international Regenerative Medicine Coalition are part of a
high-performance product development network.
Focus on the sustainable use of biological resources for medi-
cal applications in industrial biotechnology
The Leibniz Institute for Agricultural Engineering, university-related
research and biotechnology SMEs are successfully implementing
the federal government’s bioeconomics strategy and contributing
to the strength of the healthcare industries.
Development of new growth fields in the life sciences with inter-
disciplinary technologies
Cross innovation at the interface of microsystems technology, mi-
croelectronics, photonics and surface engineering and thin films
open up completely new opportunities for analytics, automation
and hardware development and along with this, for growth, value
creation and cost reduction.
Value chain expansion via inward investment and industrial
location expansion
With more than 200 biotechnology companies, over 30 research
institutions and over 130 clinics and hospitals, Berlin-Branden-
burg is already a European hot spot for the life sciences. Growth
in expertise, players and investment will reinforce the capital re-
gion’s leading position in the international markets.
This new edition of the BioTOP Report provides you with an ex-
citing, informative overview of the development in the capital re-
gion’s industries. With themes such as glyco-engineering technol-
ogy and bioelectronics, it underscores internationally outstanding
activities. We wish you reading pleasure and invite you to commit
to Berlin-Brandenburg as a place to develop your business.
Reach out and contact us!
Prof. Dr. Peter Seeberger
Dr. Günter Peine
Expert Circle Spokesman
Head of
“Biotech/Pharma“
BioTOP Berlin-Brandenburg